Polygenic Risk Score Does Not Improve Prediction of Heart Disease

Polygenic Risk Score Does Not Improve Prediction of Heart Disease

Study suggests polygenic risk scores should not be added to the standard of care for identifying high-risk coronary heart disease patients

Photo of the Today's Clinical Lab logo
Today's Clinical Lab

Today’s Clinical Lab is a reader-centric publication that keeps clinical professionals up to date with today’s rapidly changing lab industry with in-depth and timely editorial content and resources, including clinical...

ViewFull Profile
Published:Feb 24, 2020
|1 min read

Polygenic risk score—a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients—is not a useful predictive biomarker for disease risk, according to a study published in February 2020 in the Journal of the American Medical Association.

The researchers conducted a retrospective cohort study of the predictive accuracy of polygenic risk scores in 7,306 adults of European ancestry ages 45-79. The patients were taken from two large cohort studies, the Atherosclerosis Risk in Communities study and the Multi-Ethnic Study of Atherosclerosis.

They found that the polygenic risk score didn't significantly improve prediction of CHD risk in this population. It was no more useful than the conventional method of determining CHD risk, which involves assigning a patient a clinical risk score based on factors including age, gender, cholesterol levels, and tobacco use

Researchers have long sought to reduce cardiovascular mortality by early identification of CHD. The study suggests that polygenic risk scores should not be added to the standard of care for identifying high-risk CHD patients at this time; however, further study is needed to determine whether other populations may benefit from a polygenic risk score.